Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
CYCN

Cyclerion Therapeutics

$8.66

0.02 (0.23%)

08:10
10/08/19
10/08
08:10
10/08/19
08:10
Hot Stocks
Cyclerion, collaborators to present research on sickle cell disease patients »

Cyclerion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
CYCN

Cyclerion Therapeutics

$12.35

1.17 (10.47%)

07:25
09/17/19
09/17
07:25
09/17/19
07:25
Conference/Events
Cyclerion Therapeutics to hold an investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

CYCN

Cyclerion Therapeutics

$12.35

1.17 (10.47%)

04:55
09/17/19
09/17
04:55
09/17/19
04:55
Conference/Events
Cyclerion Therapeutics to hold an investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

CYCN

Cyclerion Therapeutics

$10.60

-0.01 (-0.09%)

17:34
09/11/19
09/11
17:34
09/11/19
17:34
Conference/Events
Cyclerion Therapeutics to hold an investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYCN

Cyclerion Therapeutics

$9.59

0.8 (9.10%)

10:12
08/21/19
08/21
10:12
08/21/19
10:12
Upgrade
Cyclerion Therapeutics rating change at Spin-Off Research »

Cyclerion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYCN

Cyclerion Therapeutics

$8.73

0.31 (3.68%)

08:31
08/12/19
08/12
08:31
08/12/19
08:31
Hot Stocks
Cyclerion says IW-6463 Phase 1 study remains on track for readout in Q4 »

IW-6463 first-in-human…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

CYCN

Cyclerion Therapeutics

$8.73

0.31 (3.68%)

08:30
08/12/19
08/12
08:30
08/12/19
08:30
Hot Stocks
Cyclerion says Olinciguat Phase 2 study remains on track for readout in mid-2020 »

Olinciguat Phase 2 study…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

CYCN

Cyclerion Therapeutics

$8.73

0.31 (3.68%)

08:29
08/12/19
08/12
08:29
08/12/19
08:29
Hot Stocks
Cyclerion says Praliciguat Phase 2 studies remain on track for readouts in Q4 »

Praliciguat Phase 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

CYCN

Cyclerion Therapeutics

$8.73

0.31 (3.68%)

08:28
08/12/19
08/12
08:28
08/12/19
08:28
Hot Stocks
Cyclerion Therapeutics expects proceeds to fund operations through 1Q21 »

On April 2, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

CYCN

Cyclerion Therapeutics

$8.73

0.31 (3.68%)

08:27
08/12/19
08/12
08:27
08/12/19
08:27
Earnings
Cyclerion Therapeutics reports Q2 EPS ($1.18), one est. (84c) »

"Since Cyclerion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.